1	FIThe Effects of Curcumin Supplementation on Body Weight, Body Mass Index, and Waist
2	Circumference in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of
3	Randomized Controlled Trials
4	
5	Noorbakhsh Alivand ¹ , Soleyman Alivand ² , Seyed jalil masoumi ³ , Sahar foshati ⁴ , Ebrahim Abbasi ^{5*}
6 7	
8	¹ Department of Nutrition, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
9	² Department of Biostatistical and Epidemiology, School of health, Isfahan University of Medical
10	Sciences, Isfahan, Iran.
11	³ Nutrition research center, school of nutrition and food sciences, Nutrition research center, school of
12	nutrition and food sciences,
13	⁴ Department of Nutrition, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
14	⁵ Department of Medical Entomology and Vector Control, School of Health, Shiraz University of Medical
15	Sciences, Shiraz, Iran.
16	
17	Correspondence should be sent to E. Abbasi (<u>https://orcid.org/000-993-1861-5321</u>) at
18	<u>abbasie.ebrahim@gmail.com</u> or <u>e_abbasie@sums.ac.ir</u>
19	
20	
21	Abstract
22	The study investigates the effects of curcumin on obesity and its related factors in diabetic patients, given
23	that obesity can lead to insulin resistance and complicate diabetes management. An analysis of nine
24	randomized controlled trials (RCTs) involving 699 participants was conducted to evaluate curcumin's
25	impact on body weight (BW), body mass index (BMI), and waist circumference (WC). The results
26	indicated a significant reduction in BW (WMD: -1.65 kg), BMI (WMD: -0.69 kg/m2), and WC (WMD: -
27	0.93 cm) with curcumin consumption compared to controls. Higher doses of curcumin (>1000 mg/day)
28	were notably more effective in reducing BW, BMI, and WC than lower doses. The study concludes that
29	curcumin supplementation effectively reduces BW, BMI, and WC in diabetic patients, especially at
30	higher doses, and suggests the need for further studies to explore these benefits.
31	Keywords: Curcumin, Body Mass Index, Body Weight, Waist Circumference, Obesity, Diabetes
32	
33	
34	
35	1

36 Introduction

Diabetes mellitus is a group of metabolic diseases involving hyperglycemia due to defects in insulin
secretion, action, or both or insulin resistance in skeletal muscle, liver, and adipose tissues, with a failure

39 of B-cell compensation and a relative insulin deficiency[1].

40 Recently, the incidence of diabetes has increased, and it is expected that the prevalence of type 2 diabetes

41 among adults will increase from 285 million patients in 2010 to 438 million patients in 2030. More than

42 60% of diabetic patients live in Asia, and there are more than 4 million type 2 diabetic patients in Iran[2].

43 Besides, almost 90% of T2DM patients are overweight or obese[3].

44 Obesity, in particular in the form of abdominal adiposity, is known to be associated with increased 45 morbidity and mortality[4]. Diabetes is an obesity-associated disease linked to insulin resistance and 46 hyperglycemia[5]. Recent research has shown that obesity affects more than 600 million people 47 worldwide[6]. Additionally, if scientists do not take immediate action, many people will experience 48 obesity-related disorders, such as type 2 diabetes [2]. Obesity and overweight are two major risk factors 49 for diabetes and its complications. Investigations indicate that almost 90% of diabetic patients are 50 overweight. Obesity can affect the metabolism in the body by causing insulin resistance and reducing 51 insulin secretion[7]. Therefore, the management of obesity has been strongly recommended to control 52 diabetes and its complications[3].

Various courses of action, including surgical approaches, several drugs, and lifestyle interventions, have been recommended for weight management; however, the effectiveness of these approaches is under discussion[8]. Weight reduction resulted in a greater control of T2DM[3]. Lifestyle changes, i.e., supplementation and exercise, are among the complementary treatment approaches in patients suffering from T2DM .(Diabetes Mellitus 2Type) Curcumin is one of the supplements with positive effects noticed in weight control[9, 10].

59 Curcumin is the most important component of turmeric (Curcuma longa) and is yellow. It is commonly 60 used as a food additive in Asian countries[11]. It is also deemed responsible for many medical properties 61 of turmeric. Curcumin has low toxicity and performs various pharmacological functions, including 62 antioxidant, anti-inflammatory, anti-microbial, and anti-carcinogenic effects[6, 12, 13]. In some clinical 63 trials, the desirable effects of curcumin have been shown to be a therapeutic agent for the treatment of 64 diabetes and complications of high blood glucose[6].

Moreover, several studies reported conflicting effects of curcumin consumption on body weight and composition. Some clinical trials proposed a significant effect of curcumin intake on indicators of body composition[6, 14-16]. On the contrary, others reported no significant effect of curcumin intake on body

68 weight (BW) or body mass index (BMI)[3, 17, 18]. However, despite various studies conducted on the

69 effect of curcumin intake on body composition in patients with type 2 diabetes, no prior study has

- 70 examined BW, BMI, and WC solely in diabetic patients. Thus, the current study was done to perform a
- comprehensive systematic review and meta-analysis of published randomized controlled trials (RCTs) to
- 72 independently evaluate the effect of curcumin supplementation on body weight (BW), body mass index
- 73 (BMI), and waist circumference (WC) in patients with type 2 diabetes.

74 Materials and Methods

75 The design of this systematic review and meta-analysis has been prepared according to the guidelines of

the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, 2020)

statement[19]. Furthermore, reports of included and excluded primary studies in the different stages of the

78 current systematic review have been presented using the PRISMA flow chart.

79 Search strategy

80 Our meta-analysis was designed according to the guidelines of the PRISMA statement[19]. PubMed, 81 Scopus, and ISI, Web of Sciences databases were searched for English-language reports of relevant RCTs 82 published till January 2024 for related published articles evaluating the effects of curcumin 83 supplementation on body weight, body mass index, and waist circumference. The following MeSH terms and related keywords were searched: "Curcumin "OR "Curcuminoid" OR "Curcuma" OR "Turmeric" OR 84 85 "Tumeric" OR "Curcuma longa "OR "C. longa" OR "Curcumin longa L." Details of our search strategy 86 are shown in Appendix S1. The search was not limited to the English language or human subjects. 87 Moreover, we hand-searched the reference list of included articles, related reviews, and meta-analyses. 88 PubMed's 'My NCBI' (National Centre for Biotechnology Information) email alert service was also 89 created to identify new articles that may be published after our search.

90 Study selection

91 Two investigators (N.AL and S.A) reviewed the titles and abstracts of all identified studies to ascertain 92 whether these studies are eligible for this meta-analysis based on our inclusion criteria. Discrepancies 93 were resolved by discussion with S.F. Studies were chosen for analysis according to the following 94 inclusion criteria: 1- the study was a placebo-controlled trial with either a parallel or crossover design; 2-95 conducted in patients with type 2 diabetes; 3- the effects of curcumin on body weight, body mass index 96 and waist circumference could be extracted from the article (adequate information on body indices with 97 standard deviations (SDs), standard errors (SEs), or 95% CI, at baseline and the end of follow-up in 98 intervention and control group); 4- the studies with an appropriate controlled design, i.e., the only 99 difference between the control and intervention groups was curcumin; and 5- having an intervention 100 duration of at least four weeks. Studies were excluded if 1- we could not extract the net effect of 101 curcumin; 2- curcumin supplementation duration was < 4 weeks; and 3- non-RCT studies. Furthermore, 102 studies with animal, case-control, cross-sectional, or cohort designs, lacking necessary data for extraction,

and trials without appropriate controlled design, i.e., those articles using curcumin in combination withother supplements, were excluded from this meta-analysis.

105

106 **2.3. Data extraction**

107 The following information was extracted from each of the eligible RCTs by two independent authors 108 (N.AL and F.S): first author's name, study location, year of publication, the sample size in each group, 109 type, and dose of intervention and placebo, duration of the intervention, study design (crossover or 110 parallel), patient's status and other information including age, gender, and baseline BMI. We also 111 extracted the mean and SD values of body parameters at the study baseline and end of the study. If the 112 data were reported at multiple measurements, only the values at the end of trials were used. In the studies 113 that used only one specific curcumin dose, the analysis included the dose.

114 **2.4. Quality assessment**

The risk of bias tool was applied using criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions to assess methodological quality[20]. Two independent reviewers (N.AL and FS) investigated the following criteria for each included study: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of biases. Any disagreement in the quality assessment process was resolved through discussion and consultation with a third researcher (S.F.).

122 Quantitative data synthesis and statistical analysis

We evaluated the influence of curcumin supplementation on change in the following outcomes: (I) body weight (kg), (II) BMI (kg /m2), and (III) WC (cm). Effect sizes for the meta-analysis were defined as weighted mean difference (WMD; value at the end of the trial minus the value at baseline) and 95% CI[21]. In the event of no reported SD of the mean difference, it was calculated as follows:

127 $SD\sqrt{[(= SD pretreatment)^2(+ SD posttreatment)^2]} - [(2R \times$

128 (SD pretreatment × SD posttreatment)]

In which a correlation coefficient of 0.5 was assumed as this R-value is a conservative estimate between 0 and 1[22]. When SE was reported instead of SD, we converted SE to SD for analyses: $SD = SE \times \sqrt{n}$, where n is the number of participants in each group. If interested outcomes were reported as median and range, all mean and SD values were estimated using the method described by Hozo et al[23]. Plot digitizer software was used to extract data only when the outcome variable was presented in graphic form. Pre-defined subgroup analyses were performed on supplementation duration and supplement dosage.

135 Random-effects meta-regression analysis was performed using an unrestricted maximum likelihood 136 method to explore the association between changes in body weight, body mass index, duration, and dose 137 of curcumin supplementation. Statistical heterogeneity between studies was also evaluated using Cochran's Q-test (significance set at p < 0.1) and $I^2 \ge 50\%$ assumed to indicate substantial heterogeneity 138 139 among studies). In the presence of heterogeneity, the pooled effect size was calculated using a random-140 effects model; otherwise, we applied a fixed-effects model. Sensitivity analysis was used to explore the 141 extent to which inferences might depend on a particular study using the leave-one-out method (i.e., 142 removing a single trial at a time and repeating the analyses [24]. Publication bias was assessed using 143 funnel plots, Begg's rank correlation, and Egger's weighted regression tests. In the event of publication 144 bias, the Duval and Tweedie 'trim and fill 'and 'fail-safe N 'methods were utilized[25]. All statistical 145 analyses were performed using Comprehensive Meta-Analysis (CMA) V3 software with a significance 146 level of p < 0.05.

147 **Results**

148 Selection of trials

149 The explicit research screening process is shown in Figure 1. The preliminary and additional database 150 retrieval yielded 2925 records, with 459 articles excluded due to duplicated records and 274 articles due 151 to review records. A total of 2110 items were eliminated after reading the titles and abstracts following 152 the inclusion and exclusion criteria. After reading the full texts of 82 studies, seventy-three studies were 153 excluded for the following reasons: duplicate report (n = 3), not randomized placebo-controlled studies (n 154 = 5), not providing enough information (n = 38), animal study (n = 3), vitro study (n = 3), review study (n = 3)155 = 2), no anthropometric measurements performed (n = 17) and use of curcumin in combination with other 156 components without an appropriate control group (n = 2). Nine eligible RCTs were included in the meta-157 analyses [1-3, 6, 10, 13, 26-28]. Of these, six articles reported the effects of curcumin on BW, eight 158 articles on BMI, and three on WC.

159 Characteristics of the included studies

160 Study characteristics of the 9 eligible articles are presented in Table 1. Data were pooled from these 161 studies, and the sample size ranged from 21 to 213. Overall, 1,088 participants were randomly assigned in these trials, and 699 participants (64.24%) completed the studies. The mean age of the participants ranged 162 163 from 43 to 62.5 years. One of the nine trials was performed exclusively on women [10]. The eight 164 remaining trials included both sexes. Eligible studies were published between 2014 and 2021, most of 165 which were conducted in Iran. The remaining studies were conducted in Thailand and Brazil. Seven 166 treatment arms used curcumin for the intervention. Cooked rice, Polysorbate capsules, placebo capsules, 167 maltodextrin, placebo capsules containing starch, and placebo + 10 mg piperine were used for the control 168 groups. Two treatment arms supplemented turmeric for the intervention, while the control group was

169	provided with cornstarch flour. A wide range of curcumin supplementation doses was utilized in the study
170	designs: curcumin capsules of 80 to 1500 mg/d and turmeric capsules of 2100 mg per day.
171	Supplementation duration varied from 8 to 28 weeks. Participant characteristics were also similar between
172	studies, focusing on specific patient populations, including type 2 diabetic patients (Table 2).
173	Risk of bias
174	We evaluated the quality of evidence using the Grading of Recommendations, Assessment, Development,
175	and Evaluation (GRADE) approach[29]. GRADE consists of a rating system where the quality of the
176	evidence for each outcome ranges from high to very low. The grade results are shown in Table 3. To sum
177	up, our results indicated a moderate effect of curcumin on body weight, a low effect on BMI, and a high
178	effect on WC.
	Summary of findings 179
180	The pooled estimate of curcumins on body weight, body mass index, and waist circumference
181	indices
182	The results of forest plots are illustrated in Figure 2A-C. The body weight, BMI, and WC results were
183	reported using the random-effect model because statistically significant heterogeneity was observed
184	between these studies. Combined results from six studies (174 cases and 181 controls) indicated a
185	significant decrease in body weight after curcumin consumption (WMD: - 1.65 kg, 95% CI: -3.04, -0.27,
186	p = 0.019) with significant heterogenicity between the studies (I ² = 78.67%, p = 0.000) (Fig. 2A).
187	Pooled results from eight trials (242 cases and 244 controls) showed a significant decrease in BMI in
188	curcumin consumers compared with the control group (WMD: - 0.69 kg m2, 95% CI: -0.99, -0.39, $p =$
189	0.000), with severe heterogeneity being detected ($I^2 = 92.48\%$, p = 0.000) (Fig. 2B).
190	Combined results of three studies (168 cases and 169 controls) revealed a significant reduction in WC
191	percent following curcumin consumption (WMD: - 0.93cm, 95% CI: -1.42, - 0.44, p = 0.000). There was
192	no significant heterogenicity between the studies ($I^2 = 25.65\%$, $p = 0.261$) (Fig. 2C).
193	Sensitivity analysis
194	To observe the impact of each single study on the pooled effect size, we conducted a leave-one-out
195	sensitivity analysis (Figs. 1A-C). The estimated effect size for curcumin's effect on BMI and WC was
196	robust, suggesting that removing each trial did not change the analysis results. However, by removing
197	studies of Mahsa Ahmadi Darmian [10] (WMD: -1.04 kg, 95% CI: -2.25, 0.16, p = 0.089) and Yunes
198	Panahi [26], (WMD: -1.59 kg, 95% CI: -3.04, 0.23, $p = 0.088$), the effect on body weight was no longer
199	statistically significant.
200	Subgroup analysis
201	The subgroup analyses were conducted (Table 4) to explore the effect of curcumin dose and duration on
202	the overall impact of curcumin on the estimated effect size. When the studies were stratified according to

203 the dose of curcumin consumed, as a high dose (> 1000 mg/day) or a low dose ($\leq 1000 \text{ mg/day}$), 204 significant reductions in body weight were observed in the subsets of studies with > 1000 mg/day of curcumin consumption (WMD: - 4.59 kg, 95% CI: -6.92, -2.25, p = 0.002) but not in those with ≤ 1000 205 206 g/day (WMD: - 0.93 kg, 95% CI: -2.24, 0.37, p = 0.164). Also, curcumin significantly reduced BMI in 207 doses > 1000 mg/day (WMD: -0.99, 95% CI: -1.63, -0.35, p < 0.002). This effect has also been seen in 208 doses $\le 1000 \text{ mg/day}$ (WMD: -0.21, 95% CI: -0.49, 0.05, p < 0.011). The reduction in WC was observed 209 both after consuming > 1000 mg/day of curcumin dose (WMD: -0.77 cm, 95% CI: - 0.94, -0.60, p =210 (0.000) and lower doses (WMD: -1.04 kg, 95% CI -2.30, -0.49, p = 0.002). However, it seems that the 211 reduction in the higher doses was more than the lower dose. Subgroup analysis was also performed by 212 dividing the duration of curcumin intervention (≥ 10 weeks vs. < 10 weeks). Subgroup analysis indicated 213 that curcumin consumption does not have a significant effect on reducing body weight (WMD: -1.51 kg, 214 95% CI: -3.09, 0.07, p = 0.06), BMI (WMD: -0.61, 95% CI: -1.03, -0.19, p < 0.004) and WC (WMD: -215 2.70, 95% CI: 6.65, 1.25, p = 0.18) in longer-term interventions.

216 Meta-regression

A significant association was found between changes in body weight and the dose of supplementation,

- but not with BMI (Fig. S2 panel A-B) and Table 3). Considering the duration of supplementation with
- 219 curcumin, no significant association was found.

220 Publication bias

Based on Egger's regression test, there was no evidence of publication bias for studies examining the effect of curcumin on body weight (p = 0.370), BMI (p = 0.071), and WC (p = 0.164). Furthermore, based on Begg's rank correlation tests, there was no significant publication bias for studies on body weight (p =1.000), BMI (p = 0.386), and WC (p = 1.000). Funnel plots of the impact of curcumin on body weight, BMI, and WC are illustrated in (Fig. S3A-C). Additionally, 32,827 and 43 studies would be required to bring the effect size of body weight, BMI, and WC, respectively, to a non-significant (p > 0.05) value in the analysis of the "fail-safe N" test.

228 Discussion

Limited systematic reviews and meta-analyses have been conducted on the effects of curcumin supplementation on body weight, body mass index, and waist circumference. However, the current systematic review and meta-analysis are the first studies that independently evaluate the effect of curcumin supplementation on BW, WC, and BMI from existing RCTs in diabetic patients. A metaanalysis of data from nine RCTs shows a significant effect of curcumin supplementation on BW, BMI, and WC. However, a significant reduction in BW and BMI was observed, especially at doses higher than 1000 mg/day in some trials.

236 Data obtained from this systematic review and meta-analysis examined curcumin supplementation's 237 effects on body composition indices, including in adults. In line with our study, Mousavi et al.'s results showed that curcumin supplementation significantly reduced BW and BMI compared to the control 238 239 group, and unlike our study, no significant effect of curcumin on WC[12]. The findings of a similar 240 systematic review and meta-analysis done by Akbari and Chanita Unhapipatpong demonstrated that 241 curcumin consumption leads to a significantly reduced BW, BMI, and WC, which aligns with the results 242 of our study. However, the reducing effect of curcumin on BW and BMI in our study is more than in 243 those two studies. The effect of curcumin on waist circumference (WC) in our study was found to be 244 greater than that reported by Akbari et al., likely because the participants in our study[30, 31] had similar 245 health conditions. In addition, a systematic review of clinical trials found that curcumin supplementation 246 may reduce obesity and overweight in adults[32]. However, curcumin supplementation did not change 247 BW and BMI in obese adults compared to placebo in a clinical trial[33]. Also, curcumin did not 248 significantly affect BW in patients with metabolic syndrome[17]. Several meta-analyses and clinical trials 249 were conducted, but no significant effect of curcumin on WC[12, 18, 33-35].

- Nevertheless, findings from another clinical trial investigating the effect of supplementation with curcumin (1000mg/day) on patients with non-alcoholic fatty liver disease (NAFLD) for 8 weeks showed a significant reduction in WC compared to the supplementation to placebo[36]. It should be noted that, unlike BW and BMI, WC is considered a good indicator of abdominal and general obesity[37]. Due to few available studies on the effect of curcumin supplementation on WC and their conflicting results on the effect of curcumin supplementation on BW, BMI, and WC, further studies are required to reach a firm conclusion in this area[38].
- 257 The subgroup analysis reveals some differences, such as significant reductions in BW observed in the 258 subsets of studies with > 1000 mg/day dose of curcumin consumption (p = 0.002) but not in those with \leq 259 1000 g/day (p = 0.164). Also, curcumin had a significant effect in reducing BMI in doses > 1000 mg/day 260 (p < 0.002); this effect has also been seen in doses $\leq 1000 \text{ mg/day}$ (p < 0.011). The reduction in WC was 261 observed both after consuming doses > 1000 mg/day of curcumin (p = 0.000) and lower doses (p =262 0.002). However, it seems that the reduction in the higher dose was more significant than the lower dose. 263 These findings indicate that higher doses of curcumin have a greater effect on anthropometric indices in 264 diabetic patients.
- Curcumin is the most important ingredient of turmeric (curcuma longa) and is yellow. Curcumin is comm
 only used as a food additive in Asian countries [3[6]. This substance also has therapeutic properties. It is
- 267 an active ingredient of turmeric that has antioxidant and anti-inflammatory properties. Currently, the US
- 268 Food and Drug Administration (FDA) has approved curcumin as Generally Recognized as Safe
- 269 (GRAS)[28, 39], and the European Food Safety Authority (EFSA) has recommended an acceptable dose

of 3 mg/kg/d[40]. Several studies have shown that curcumin has an acceptable safety profile with minimal
side effects[41, 42]. Curcumin has been shown to have several therapeutic benefits for various diseases,
such as metabolic syndrome, type 2 diabetes, hyperlipidemia, and Alzheimer's disease[1, 3, 27, 43].
However, a major limitation of curcumin as an agent with an oral route of administration is its low
bioavailability due to its poor absorption in the gastrointestinal tract, rapid metabolism, and fast
elimination from systemic circulation[1, 44].

On the other hand, obesity is a global health problem and a major risk factor for type 2 diabetes. Our meta-analysis shows the beneficial effects of curcumin supplementation in reducing BMI, BW, and waist circumference, confirming the results of the latest studies[45].

279 The mechanisms by which curcumin affects body weight and BMI are unclear. Nonetheless, previous 280 studies suggest several mechanisms through which curcumin may play a role in weight loss. Curcumin 281 down-regulates Janus Kinase (JNK) enzyme, which has been suggested to have a fundamental role in 282 obesity pathogenesis[1, 46, 47]. Curcumin can also inhibit the11bHSD-1enzyme that activates cortisol, 283 and higher cortisol concentrations in adipocytes induce central obesity[48]. In addition, curcumin 284 promotes fatty acid oxidation and increases adipocyte apoptosis. In addition, curcumin inhibits NF-kB in 285 adipose tissue, resulting in a reduced level of inflammatory cytokines, for example, tumor necrosis factor 286 α (TNFa), IL-1, IL-6, monocyte chemotactic protein 1, and plasminogen activator inhibitor type 1. 287 Curcumin has also been revealed to increase adiponectin levels [6, 13, 27]. It reduces obesity by inhibiting 288 adjocyte differentiation in the early stages through the suppression of the transcription factor 289 Proliferator-Activated Receptor-c (PPAR-c) and by activating adenosine monophosphate-activated 290 protein kinase (AMPK), which in turn enhances lipolysis[3, 26].

Finally, the dysbiosis of the intestinal microbiota is also one of the pathogens of obesity, and curcumin acts as a prebiotic, distributing in the intestines and influencing the composition and diversity of the microbiota. However, the effect of curcumin on obesity via gut microbiota homeostasis is still controversia[26, 49, 50]. This study showed that curcumin supplementation can reduce body weight, BMI, and WC in patients with type 2 diabetes, which can effectively reduce insulin sensitivity in type 2 diabetes patients.

297 limitations and strengths

Our systematic review has several limitations. Firstly, most of the included RCTs were performed in Iran. Therefore, differences in daily curcumin intake and lifestyle may be underestimated. Secondly, curcumin may have different effects on males and females because of its different fat content, but there was just one article that focused solely on females and no articles on males. Clinical trials are necessary to assess curcumin's effects on anthropometric variables separately in males and females. Third, the treatment

duration in most articles was short. Only two articles reported a study that followed participants for over 12 weeks. Fourth, the significant heterogeneity among studies shows that the effects of curcumin on BW, BMI, and WC should be further investigated. The fifth, the removal of an individual study or a group of studies, as assessed by sensitivity analysis, did not have a significant effect on BMI and WC results. However, the removal of two studies related to BW had a significant effect on the findings. Finally, the number of studies related to WC was less than the appropriate number to perform the regression test, so the regression test was not performed on this index.

- 310 It should be noted that this study was not registered with Prospero. This systematic review has some 311 strength. To the best of our knowledge, this study is the first meta-analysis that independently evaluates the effect of curcumin supplementation on BW, WC, and BMI in diabetic patients. No evidence of 312 313 publication bias was seen in this meta-analysis, as examined by the Egger and Begg regression test; in our 314 systematic review, curcumin dose ranged from low to high; therefore, the effects of dose were considered 315 in this systematic review. Also, the included studies were of moderate and high methodological quality. 316 They were done on participants with the same disease. Besides, based on RAB1 quality assessment 317 guidelines, most studies were of moderate and high quality. In addition, we could find sources of
- between-study heterogeneity in our subgroup analyses.
- 319 Conclusion
- 320 In our meta-analysis, sufficient evidence was found regarding curcumin's significant effect on BW, BMI,
- and WC. However, more evident doses higher than 1000 mg/day are required. Therefore, additional high-
- 322 quality, well-designed studies should be performed to approve our findings.
- 323 Declaration
- 324 Funding
- 325 This study received no grants from commercial, public, or nonprofit entities.
- 326 Competing interests
- 327 The authors declare that they have no competing interests.
- 328 Data availability statements
- All data obtained from this research are included in the article's main text.
- 330 Author contributions
- 331 NAL, SF, and EA conceived the study. NAL carried out the literature search and wrote the manuscript.
- 332 NAL and SAL carried out data extraction and independent reviewing. NAL, EA, and SF assessed the
- quality of the included studies. NAL and SF performed data analysis and interpretation, and SJM revised
- the manuscript. The manuscript has been read and approved by all authors.
- 335 Ethical approval and consent to participate

Cons	sent to participate
Not a	applicable.
	sent to publication author fully consents to the publication of the article.
Refe	rences
1.	Rahimi, H.R., et al., The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid
	profile in diabetic subjects: a randomized clinical trial. Avicenna journal of phytomedicine,
	2016. 6 (5): p. 567.
2.	Adab, Z., et al., Effect of turmeric on glycemic status, lipid profile, $hs \square CRP$, and total
	antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytotherapy Research,
	2019. 33 (4): p. 1173-1181.
3.	Ebrahimkhani, S., S. Ghavamzadeh, and A. Mehdizadeh, The effects of vitamin D and
	curcuminoids supplementation on anthropometric measurements and blood pressure in type 2
	diabetic patients with coexisting hypovitaminosis D: A double-blind, placebo-controlled
	randomized clinical trial. Clinical nutrition ESPEN, 2020. 37: p. 178-186.
	Ramsey, S.D., et al., Varroa destructor feeds primarily on honey bee fat body tissue and not
	hemolymph. Proceedings of the National Academy of Sciences, 2019. 116(5): p. 1792-1801.
•	Baziar, N. and M. Parohan, The effects of curcumin supplementation on body mass index, body
	weight, and waist circumference in patients with nonalcoholic fatty liver disease: a systematic
	review and dose-response meta \Box analysis of randomized controlled trials. Phytotherapy
	Research, 2020. 34 (3): p. 464-474.
•	Hodaei, H., et al., The effect of curcumin supplementation on anthropometric indices, insulin
	resistance and oxidative stress in patients with type 2 diabetes: A randomized, double-blind
	clinical trial. Diabetology & metabolic syndrome, 2019. 11: p. 1-8.
7.	Verma, S. and M.E. Hussain, Obesity and diabetes: an update. Diabetes & Metabolic Syndrome:
	Clinical Research & Reviews, 2017. 11 (1): p. 73-79.
8.	Aucott, L.S., Influences of weight loss on long-term diabetes outcomes: symposium on 'diet and
	diabetes'. Proceedings of the Nutrition Society, 2008. 67(1): p. 54-59.

336

337

338

339 340

341 342 343

344

345 346

347

348 349

350

351

352

353

354

355

356

357

358 359

360

361

362

363

364

365

- 366 9. Abbasi, E., A review of cultural aspects and barriers to the consumption of edible insects. Health 367 Science Monitor, 2024. 3(3): p. 179-194.
- 368 Darmian, M.A., et al., How combined and separate aerobic training and turmeric 10. 369 supplementation alter lipid profile and glycemic status? A clinical trial in middle-aged females

370 *with type 2 diabetes and hyperlipidemia.* International Cardiovascular Research Journal, 2021.


371 15(3).

- Adab, Z., et al., *Effect of turmeric on body measurement indices, glycemic condition, and lipid profile in hyperlipidemic patients with type 2 diabetes.* Iranian Journal of Nutrition Sciences and
 Food Technology, 2013. 8(3): p. 217-227.
- Mousavi, S.M., et al., *The effects of curcumin supplementation on body weight, body mass index and waist circumference: a systematic review and dose-response meta-analysis of randomized controlled trials.* Critical reviews in food science and nutrition, 2020. 60(1): p. 171-180.
- Asadi, S., et al., *Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo- controlled clinical trial.* Complementary therapies in medicine, 2019. 43: p. 253-260.
- 14. Navekar, R., et al., *Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases.* Journal of the American College of Nutrition,
 2017. 36(4): p. 261-267.
- Panahi, Y., et al., *Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a clinical study.* Journal of Asian natural products research, 2018.
- Rahmani, S., et al., *Treatment of non* □*alcoholic fatty liver disease with curcumin: A randomized placebo* □*controlled trial.* Phytotherapy Research, 2016. **30**(9): p. 1540-1548.
- Yang, Y.S., et al., Lipid lowering effects of curcumin in patients with metabolic syndrome: a *randomized*, double blind, placebo controlled trial. Phytotherapy research, 2014. 28(12): p.
 1770-1777.
- 18. Campbell, M.S., et al., *Responsiveness to curcumin intervention is associated with reduced aortic stiffness in young, obese men with higher initial stiffness.* Journal of Functional Foods, 2017. 29:
 p. 154-160.
- Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* Bmj, 2021. **372**.
- Higgins, J.P., et al., *The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.* Bmj, 2011. 343.
- 398 21. Borenstein, M. and H. Rothstein, *Comprehensive meta-analysis*. 1999: Biostat.
- Reeves, B.C., et al., *Including non □randomized studies*. Cochrane handbook for systematic
 reviews of interventions: Cochrane book series, 2008: p. 389-432.
- 401 23. Hozo, S.P., B. Djulbegovic, and I. Hozo, *Estimating the mean and variance from the median*,
 402 *range, and the size of a sample.* BMC medical research methodology, 2005. 5: p. 1-10.

- 403 24. Sahebkar, A., Are curcuminoids effective C□reactive protein□lowering agents in clinical
 404 practice? Evidence from a meta□analysis. Phytotherapy research, 2014. 28(5): p. 633-642.
- 405 25. Duval, S. and R. Tweedie, *Trim and fill: a simple funnel-plot-based method of testing and*406 *adjusting for publication bias in meta-analysis.* Biometrics, 2000. 56(2): p. 455-463.
- Panahi, Y., et al., Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory
 biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebocontrolled trial. Drug research, 2018. 68(07): p. 403-409.
- Chuengsamarn, S., et al., *Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.* The Journal of nutritional biochemistry,
 2014. 25(2): p. 144-150.
- 413 28. Neta, J.F.d.F., et al., *Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic*414 *control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical*415 *trial.* International journal of food sciences and nutrition, 2021. **72**(7): p. 968-977.
- 416 29. Guyatt, G.H., et al., *GRADE guidelines: a new series of articles in the Journal of Clinical*417 *Epidemiology.* Journal of clinical epidemiology, 2011. 64(4): p. 380-382.
- 418 30. Chanita Unhapipatpong, M., *The Effect of Curcumin Supplementation on Weight Loss and*419 Anthropometric Indices: An Umbrella Review and Updated Meta-analyses of Randomized
 420 Controlled Trials. Department of Clinical Epidemiology and Biostatistics, Faculty of
 421 Medicine
- 422 31. Akbari, M., et al., *The effects of curcumin on weight loss among patients with metabolic*423 syndrome and related disorders: a systematic review and meta-analysis of randomized controlled
 424 trials. Front Pharmacol 10: 649. 2019.
- 425 32. Hariri, M. and F. Haghighatdoost, *Effect of curcumin on anthropometric measures: a systematic*426 *review on randomized clinical trials.* Journal of the American College of Nutrition, 2018. 37(3):
 427 p. 215-222.
- Mohammadi, A., et al., *Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.* Phytotherapy Research, 2013. 27(3): p. 374-379.
- 430 34. Mohammadi, A., et al., *Effects of curcumin on serum vitamin E concentrations in individuals with*431 *metabolic syndrome.* Phytotherapy research, 2017. **31**(4): p. 657-662.
- 432 35. Di Pierro, F., et al., Potential role of bioavailable curcumin in weight loss and omental adipose
 433 tissue decrease: preliminary data of a randomized, controlled trial in overweight people with
 434 metabolic syndrome. Preliminary study. European Review for Medical & Pharmacological
 435 Sciences, 2015. 19(21).

- 436 36. Panahi, Y., et al., *Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease:*437 *a randomized controlled trial.* Drug research, 2017. **67**(04): p. 244-251.
- 438 37. Gearon, E., et al., *Changes in waist circumference independent of weight: Implications for*439 *population level monitoring of obesity.* Preventive medicine, 2018. **111**: p. 378-383.
- Jalali, M., et al., *The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.* Complementary therapies in medicine, 2020. 48:
 p. 102283.
- Bethesda, M., *Drugs and lactation database (LactMed)*. National Library of Medicine (US):
 Bethesda, MD, USA, 2006.
- 446 40. Additives, E.P.o.F. and N.S.a.t. Food, *Scientific opinion on the re* □*evaluation of curcumin (E*447 100) as a food additive. EFSA journal, 2010. 8(9): p. 1679.
- 448 41. Hewlings, S.J. and D.S. Kalman, *Curcumin: A review of its effects on human health.* Foods, 2017.
 449 6(10): p. 92.
- 42. Lao, C.D., et al., *Dose escalation of a curcuminoid formulation*. BMC complementary and
 alternative medicine, 2006. 6(1): p. 10.
- 43. Masella, R. and F. Cirulli, *Curcumin: a promising tool to develop preventive and therapeutic*strategies against non-communicable diseases, still requiring verification by sound clinical trials.
 2022, MDPI. p. 1401.
- 455 44. Gopinath, H. and K. Karthikeyan, *Turmeric: A condiment, cosmetic and cure.* Indian journal of
 456 dermatology, venereology and leprology, 2018. 84: p. 16.
- 45. Sun, Z., et al., The effects of curcumin on anthropometric and cardiometabolic parameters of
 patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of
 randomized controlled trials. Critical reviews in food science and nutrition, 2023. 63(28): p.
 9282-9298.
- 46. Panahi, Y., et al., *Curcuminoids plus piperine modulate adipokines in type 2 diabetes mellitus.*462 Current clinical pharmacology, 2017. 12(4): p. 253-258.
- 463 47. Alidadi, M., et al., *The effect of curcumin supplementation on pulse wave velocity in patients with*464 *metabolic syndrome: a randomized, double-blind, placebo-controlled trial.* Pharmacological
 465 properties of plant-derived natural products and implications for human health, 2021: p. 1-11.
- 466 48. Akbari, M., et al., *The effects of curcumin on weight loss among patients with metabolic*467 *syndrome and related disorders: a systematic review and meta-analysis of randomized controlled*468 *trials.* Frontiers in pharmacology, 2019. **10**: p. 439144.


469 470	49.	Vamanu, E. and S.N. Rai, <i>The link between obesity, microbiota dysbiosis, and neurodegenerative pathogenesis.</i> Diseases, 2021. 9 (3): p. 45.
471	50.	Kasprzak-Drozd, K., et al., Curcumin and weight loss: does it work? International journal of
472	001	molecular sciences, 2022 . 23 (2): p. 639.
473		
474		
475		
476		
477		
478		
479		
480		
481		
482		
483		
484		
485		
486		
487		
488		
489		
490		
491		
492		
493		




Study name	Statistics for each study							Difference in	means and 95% Cl
	Difference in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value		
Homa Hodaei(2019)	-1.190	3.825	14.628	-8.686	6.306	-0.311	0.756		
Mahsa Ahmadi Darmian(2021	-5.150	1.364	1.861	-7.824	-2.476	-3.775	0.000		
Sara Asadia(2019)	-0.400	0.282	0.079	-0.952	0.152	-1.421	0.155		•
Shirin Ebrahimkhani(2020)	-0.070	0.796	0.634	-1.630	1.490	-0.088	0.930	-	🖷 -
′unes Panahi(2017)	-2.140	0.418	0.175	-2.960	-1.320	-5.117	0.000		
Cohreh Adab(2018)	-3.920	3.160	9.987	-10.114	2.274	-1.240	0.215	K =	<u> </u>
	-1.659	0.708	0.501	-3.046	-0.271	-2.344	0.019		
								-10.00 -5.00	0.00 5.00 10.00
								Favours curcumin	Favours control

body weight


502 Figure 2A. The body weight, BMI, and WC results were reported using the random-effect model.





Body mass index(BMI)

Fig 2B. Pooled results from eight trials showed a significant decrease in BMI in curcumin consumerscompared with the control group.



Waist Circumference(WC)

Fig 2C. Combined results of three studies revealed a significant reduction in WC percent followingcurcumin consumption.

First author (publication year)	Country	Sample size (M/F, Intervention/ Control)	Target population	Mean age (yr)	BMI (kg/m ²)	Study design (randomization, blinding)	Intervention group	Control group	Dose (mg/d)	Duration (w)	Results
Hamid Reza Rahimi (2015)	Iran	70 (31/39, 35/35)	T2DM	56.3	-	Parallel (yes, double)	Curcumin	placebo	80	12	↓ BMI
Homa Hodaei (2019)	Iran	44 (22/22, 21/23)	T2DM	58	18.5-35	Parallel (yes, double)	Curcumin capsules	cooked rice	1500	10	↓ BW, ↓ BMI, ↓ WC,
Joana Furtado de Figueiredo Neta, (2021)	Brazil	61 (14/47, 33/28)	T2DM	62.5	-	Parallel (yes, double)	curcumin capsules plus 5mg piperine	Placebo capsules	500	17	↓ BMI,
Mahsa Ahmadi Darmian (2021)	Iran	21 (0/21, 11/10)	T2DM	44.3	25-30	Parallel (yes, single)	turmeric capsules	Corn starch flour capsules	2100	8	↓ BW, ↓ BMI,
Sara Asadia (2019)	Iran	80 (10/70, 40/40)	T2DM	53.3	25-39.9	Parallel (yes, double)	curcumin capsules	Polysorbate capsules	80	8	$\downarrow BW, \downarrow BMI, \\ \downarrow WC$
Shirin Ebrahimkhani (2020)	Iran	35 (13/22, 16/19)	T2DM	56.1	-	Parallel (yes, double)	curcumin	maltodextrin	500	12	$\substack{\leftrightarrow, \mathrm{BW},\\ \leftrightarrow, \mathrm{BMI},}$
Somlak Chuengsamarn (2014)	Thailand	213 (/97,116 107/106)	T2DM	59.1	-	Parallel (yes, double)	curcumin capsules	placebo capsule contains starch	1500	25	↓WC,
Yunes Panahi (2017)	Iran	100 (51/49, 50/50)	T2DM	43	-	Parallel (yes, double)	curcumin plus 10 mg piperine	PLASEBO+ 10MG PIPERINE	1000	12	↓ BW, ↓ BMI,
Zohreh Adab (2018)	Iran	75 (36/39, 36/39)	T2DM	54.7	-	parallel (yes, double)	turmeric supplement	corn starch flour	2100	8	↓ BW, ↓ BMI,

Table 1. Main characteristics of the included studies.

Symbols: \downarrow , significant decrease; \uparrow , significant increase; \leftrightarrow , no significant difference.

Abbreviations: BW; body wight, BMI, body mass index; WC, waist circumference

Table2 Quality assessment of clinical trials (according to Cochrane guideline) The effects of curcumin supplementation on body wight, body mass index and waist circumference in patients with type 2 diabetes.

Study	Random Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	incomplete outcome data	Selective outcome reporting	Other potential sources of biases	General Risk of Bias
Hamid Reza Rahimi (2015)	L	Н	L	U	L	Н	L	Moderate
Homa Hodaei (2019)	L	U	L	L	L	L	L	Low
Joana Furtado de Figueiredo Neta, (2021)	U	Н	L	Н	L	Н	Н	High
Mahsa Ahmadi Darmian (2021)	L	Н	Н	Н	L	Н	Н	High
Sara Asadia (2019)	L	Н	L	U	L	L	L	Low
Shirin Ebrahimkhani (2020)	L	U	L	U	L	Н	L	Low
Somlak Chuengsamarn (2014)	L	L	L	U	L	Н	L	Low
Yunes Panahi (2017)	Н	Н	L	Н	L	Н	Н	High
Zohreh Adab (2018)	L	Н	L	U	L	Н	L	Moderate

H: High, M: Moderate, L: Low

Table 3 Grade profile of Curcumin supplementation on Body weight, BMI and WC

		Quality as	ssessment				Summary of findings	
Outcomes	Risk of bias	Inconsistency	Indirectne	Imprecision	Publication	Number of	WMD, 95% CI	Quality of
			SS		bias	intervention/co		evidence
						ntrol		
Body weigh	NO Serious	Serious	NO Serious	NO Serious	NO Serious	174/181	-1.65(-3.04, -0.27)	moderate
	limitation	limitation	limitation	limitation	limitation			
BMI	NO Serious	Very Serious	NO Serious	NO Serious	NO Serious	242/244	-0.69(-099, -0.39)	Low
	limitation	limitation	limitation	limitation	limitation			
WC	NO Serious	NO Serious	NO Serious	NO Serious	NO Serious	168/169	-0.93(-1.42, -0.44)	High
	limitation	limitation	limitation	limitation	limitation			-

Variables	Dos	se (mg/day)	Duration (w	eeks)
Body wigt (Kg)	>1000	≤1000	≥10 weeks	<10 weeks
Number of Comparisons	3	3	3	3
WMD (95% CI)	- 4.59	- 0.93	-1.24	-2.83
	(-6.92, -2.25)	(-2.24, 0.37)	(-2.98, 0.49)	(-6.68, 1.00)
p value	0.002	0.164	0.161	0.148
I2 (%)	0.605	84.63	62.38	84.28
P heterogeneity	0.000	0.001	0.070	0.002
BMI (kg/m2)	>1000	≤1000	≥10 weeks	<10 weeks
Number of Comparisons	4	4	4	4
WMD (95% CI)	-0.99	-0.21	-0.61	-0.73
	(-1.63, -0.35)	(-0.49, 0.05)	(-1.03, -0.19)	(-1.10, -0.36)
p value	< 0.002	< 0.011	< 0.004	0.000
I2 (%)	96.64	16.27	33.76	95.85
P heterogeneity	0.000	0.310	0.210	0.000
WC (cm)	>1000	≤1000	≥10 weeks	<10 weeks
Number of Comparisons	2	1	1	2
WMD (95% CI)	-0.77	-1.04	-2.07	-0.92
	(-0.94, -0.60)	(-2.30, -0.49)	(-6.65, -1.25)	(-1.45, -0.39)
p value	0.000	0.002	0.181	0.001
I2 (%)	0.000	0.000	0.000	44.37
P heterogeneity	0.340	1.000	1.000	0.180

Table 4 Results of subgroup analysis of included randomized controlled trials in the meta-analysis of curcumin supplementation and Body wight, BMI and WC - related parameters.

model		Random effect	
	Slope	95%CI	P value
Body wight			
Dose of supplementation	-0.0020	-0.002 to -0.001	0.000
Intervention duration	0.3467	-0.630 to 1.324	0.486
BMI			
Dose of supplementation	-0.0005	-0.0011 to 0.0001	0.096
Intervention duration	0.94	-0.085 to 0.275	0.303

Table 5 Meta-regression between changes in Body Weight and was found with changes in Body wight and BMI (Fig. 5 panel A-B and Table 3).

BMI and administered doses and intervention duration of curcumin

	Corrected effect size	Begg's rank correlation				Fail-safe N Test				
	WMD 95% CI	Kendall's tau	z value	p value	Intercept	95% C	t value	df	p value	n
Body	-1.65 (-3.04, -0.27)	0.000	0.000	1.000	-1.38	(-5.18,2.48)	1.007	4.0	0.370	32
wight										
BMI	-0.69 (-0.99, -0.39)	-0.25	0.86	0.386	-2.52	(5.34,0.30)	2.183	6.0	0.071	82
WC	-0.93 (-1.42,0.44)	0.000	0.000	1.000	-1.27	(-5.56,3.01)	3.78	1.0	0.164	43

Table 6 Assessment of publication bias in the impact of curcumin on Body wight, Body mass index and Waist circumference in patients with type 2 diabetes

Abbreviations: BMI, body mass index; WC, waist circumference; WMD, weight mean difference.